=90% (LC/MS-ELSD);W1207;(1R,18S,19R,20S)-19-Ethenyl-18-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-17-">
Vincosamide

CAS No.:23141-27-7

TBW01737
Oxayohimban-21-one,19,20-didehydro-16-ethenyl-17-(b-D-glucopyranosyloxy)-, (3b,15b,16a,17b)-;(3β,15β,16α,17β)-21-Oxo-16-vinyl-19,20-didehydro-18-oxayohimban-1 7-yl β-D-glucopyranoside;Vincosamide;C16724;Strictosamide;strictosamine;strictosidine lactam;vincoside lactam;[ "Vincoside lactam" ];(1S,20R)-19-Ethenyl-18-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-17-oxa-3,13-diazapentacyclo[;C26H30N2O8;YAA14127;BDBM50531280;Vincosamide, >=90% (LC/MS-ELSD);W1207;(1R,18S,19R,20S)-19-Ethenyl-18-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-17-
inquiry
C26H30N2O8
498.53

Product introduction

Category: Alkaloids
Appearance: powder
Purity: 95~98%(HPLC)
Storage conditions: -20°C under seal save, placed in ventilated, dry environment
Application: All our products are for research and lab only. Injecting, eating and other ways are forbidden.
Package: 5mg,10mg ,20mg ,50mg ,100mg,1g, 100g or customized
SMILES: O1C([H])=C2C(N3C([H])([H])C([H])([H])C4C5=C([H])C([H])=C([H])C([H])=C5N([H])C=4[C@@]3([H])C([H])([H])[C@@]2([H])[C@@]([H])(C([H])=C([H])[H])[C@]1([H])O[C@@]1([H])[C@@]([H])([C@]([H])([C@@]([H])([C@@]([H])(C([H])([H])O[H])O1)O[H])O[H])O[H])=O